Oripavine (Morphinan Alkaloid · Buprenorphine Precursor · Etorphine Chemistry · Informational)
| Compound | Oripavine (3-O-Demethylthebaine) |
| Chemical class | Alkaloid — Isoquinoline / Morphinan (Thebaine phenol; controlled pharmaceutical precursor) |
| CAS | 467-04-9 |
| Primary source | Papaver bracteatum (Persian poppy, major alkaloid alongside thebaine), Papaver orientale |
| Key applications | Pharmaceutical precursor to buprenorphine, nalbuphine, etorphine; Schedule II controlled; informational reference |
| Claim strength | High (pharmaceutical derivatives); Not applicable (oripavine itself) |
| Typical form | Pharmaceutical raw material; not a clinical drug itself; Schedule II controlled substance |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Papaver orientale (oriental poppy), a primary source. Oripavine is the 3-O-demethylated analogue of thebaine — it has a 3-hydroxyl where thebaine has a 3-methoxy group. This structural difference makes oripavine more directly useful as a precursor for certain semi-synthetic opioids where the 3-hydroxyl is required. Pharmaceutical significance: Like thebaine, oripavine is a pharmaceutical raw material rather than a clinical drug. It is the precursor for: buprenorphine (via 7-alpha-acetylthebaine route), nalbuphine (mixed agonist-antagonist opioid), etorphine (the most potent opioid known — 1,000–3,000× more potent than morphine, used in veterinary large-animal anaesthesia), and diprenorphine (the etorphine reversal agent). Etorphine context: Etorphine (3-hydroxy-4,5α-epoxy-6α-[[2-(tetrahydropyranyl)oxy]acetyl]-N-cyclopropylmethyl-6,14-endo-ethenomorphine) is an oripavine-derived opioid 1,000–3,000× more potent than morphine by weight. Even nanogram quantities can be lethal to humans. It is used exclusively as “M99” in veterinary field immobilisation of large animals (elephants, rhinos, giraffes) where the high potency allows effective delivery in very small volumes. Handling etorphine requires extreme precautions including antidote (diprenorphine) on hand. Regulatory status: Schedule II controlled substance in the US and equivalent in most markets.
Oripavine — Pharmaceutical Chemistry Context
Papaver bracteatum cultivation for oripavine: P. bracteatum naturally accumulates both thebaine and oripavine, with the ratio depending on the specific cultivar and growing conditions. Agricultural programmes in Tasmania and other regions have selectively bred P. bracteatum cultivars to maximise thebaine + oripavine yields for the pharmaceutical industry. The P. bracteatum alkaloid profile (thebaine + oripavine, minimal morphine/codeine) is ideal for pharmaceutical precursor supply without diversion-risk opioids. Agricultural reference.
Buprenorphine synthesis via oripavine route: The alternative buprenorphine synthesis from oripavine (versus from thebaine via the Diels-Alder route) offers some manufacturing advantages in specific contexts. Oripavine’s 3-hydroxyl eliminates one O-demethylation step required in the thebaine route. The specific semi-synthetic pathway chosen for commercial buprenorphine production depends on precursor availability and manufacturing costs. Pharmaceutical chemistry reference.
Etorphine — most potent clinically-used opioid: Etorphine (M99) potency relative to morphine: approximately 1,000–3,000× by weight. A dose of 2–4 mg etorphine is sufficient to immobilise an adult elephant (approximately 4,000 kg). Accidental human etorphine exposure (needle-stick, skin absorption from a contaminated surface) can be rapidly fatal — wildlife veterinarians using etorphine work in teams with diprenorphine (etorphine reversal agent) and naloxone immediately available. Etorphine for veterinary use in the UK is controlled under a specific veterinary exemption from Misuse of Drugs regulations. Critical safety reference for any context involving oripavine derivatives.
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Oripavine
Is oripavine naturally occurring or synthetic?
Oripavine occurs naturally — it is produced by Papaver bracteatum and P. orientale as a primary alkaloid. Unlike most synthetic pharmaceutical precursors, oripavine is extracted directly from plant material. This gives it a different regulatory and supply chain character from purely synthetic precursors — its production is tied to controlled cultivation of specific poppy species under international narcotics control.
What makes etorphine so much more potent than morphine?
Etorphine’s exceptional potency derives from structural features that maximise mu-opioid receptor affinity and slow receptor dissociation: (1) the C7 methylene bridge and C6 acetyloxy group create a rigidified structure that fits the MOR binding pocket with high affinity; (2) the N-cyclopropylmethyl group (same as buprenorphine) increases binding affinity; (3) the overall lipophilicity ensures rapid CNS penetration. The cumulative result is an opioid approximately 1,000–3,000× more potent than morphine — a potency level that cannot be practically used in humans but enables safe large animal immobilisation with millilitre-volume injections.
Why is Papaver bracteatum preferred over P. somniferum for pharmaceutical precursor production?
Two key reasons: (1) P. bracteatum accumulates predominantly thebaine/oripavine with minimal morphine and codeine — the diversion-risk alkaloids that require strict controls when present. This simplifies regulatory compliance for pharmaceutical manufacturers. (2) P. bracteatum is a more vigorous plant with potentially higher alkaloid yields per hectare in appropriate growing conditions. The tradeoff is that P. bracteatum cultivation is less geographically established than P. somniferum and requires different agronomic expertise.
Is there any legitimate non-pharmaceutical use for oripavine?
No — oripavine has no established therapeutic use and no supplement, food, or cosmetic application. Its sole commercial significance is as a pharmaceutical raw material for semi-synthetic opioid synthesis. The cultivation, extraction, and possession of oripavine outside of specifically licensed pharmaceutical manufacturing contexts is a controlled substance violation in essentially all jurisdictions.
Related compounds: Thebaine, Morphine, Codeine, Papaverine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery